Johnson & Johnson took a step closer to developing COVID-19 vaccine

Johnson & Johnson, a global general pharmaceutical company,

which is a well known brand of Johnson's Baby, Tylenol, Listerine, etc., is a global pharmaceutical company founded in 1885. They produce a variety of products, including medicines, medical supplies, and daily necessities. It is one of the world's top 500 companies selected by the economics magazine Fortune, as well as competing with the Pfizer for the world’s first and second place. Currently, there are over 250 subsidiaries in over 60 countries, and the number of employees are known to be about 128,000 (excerpt from Naver Knowledge Encyclopedia).

🔺 jnj.com

Johnson & Johnson's COVID-19 vaccine clinical trial plan,

Johnson & Johnson began research on the production of vaccines for COVID-19 in January this year. Several vaccine candidates have been extracted through AdVac® and PER.C6, a vaccine manufacturing technology platform of Janssen Pharmaceutica, a subsidiary of Johnson & Johnson. Testing in collaboration with Harvard University's research team revealed that they identified the most effective vaccine for coronavirus treatment.

Johnson & Johnson plans to start clinical trials for candidates starting in September with a 
$ 1 billion investment with the US government. Even though it is administered to the human body, he said he was convinced that there would be no problems with safety because they used technology platforms that manufactured Ebola, Zika, and AIDS vaccines. If the results are good, it is expected to be available in early 2021. President Alex Gorski of Johnson & Johnson said, "We are competing with COVID-19, not with other companies, and we will provide this vaccine at a low price”.

🔺 wipsglobal.com
< EP patent, which is related to PER.C6 >

Speeding up the search for a medicine,

Korean and overseas pharmaceutical companies are also trying to find COVID-19 treatment. In order to shorten the developing period of new drugs that take about 10 years on average, they are implementing strategies to find efficacy in drugs that have been released already or are being developed. There are also companies that have abandoned their patents and allowed the development of generic drugs for the public good.

🔺 celltrion.com

Gilead's “Remdesivir” and Abbvie ’s “Kaletra”, 
which are known to have good therapeutic effects, are expected to have a result of the clinical test soon, and expectations are raising for approval. However, there are also opinions that the probability of failure is also high, and it is too early to expect. SK Bioscience, GC Green Cross, Celltrion, and IL-YANG Pharmaceutical have also entered the development of coronavirus vaccines and treatments, but it is still in the process of discovering candidates or experimenting with cells/animals, so it seems that it will still take more time to enter human clinical trials.

🔺 janssen.com

Hopefully that a cure for everyone will come out,

Now that the coronavirus is spreading rapidly all over the world, finding the treatment is the most urgently needed. News articles predicting the timing of development are overflowing, but the anxiety seems to grow more and more, as nothing has been decided yet. We hope that good results will come out as soon as possible, as Johnson & Johnson and other companies around the world are trying.